The aim is to compare the effect of two larger doses given three weeks apart with two smaller doses given on the same schedule, to see which approach better prevents a return to heavy drinking after a period of detoxification. Participants will receive the assigned capsules, attend regular check‑in visits, and record their drinking using a calendar method that helps recall daily alcohol use.

During the six‑month follow‑up, researchers will note the first day a participant drinks a large amount (defined as at least 60 g of alcohol) and will collect information on mood, anxiety, and overall quality of life at several points. Blood samples will also be taken at the start and near the end of the study to monitor safety.

The purpose of the study is to understand if oxytocin can help improve social interactions in young adults who have high alcohol consumption. Participants will receive either the oxytocin nasal spray or a placebo during the study. The study will involve two visits where participants will be asked to complete tasks that measure their social behavior, impulsivity, emotion recognition, social learning, and alcohol craving. These tasks will help researchers understand the effects of the treatment on different aspects of behavior and emotions.

The study is designed to be completed over a short period, with participants attending two sessions. During these sessions, they will be monitored and asked to perform various tasks to assess changes in their behavior and emotional responses. The results of this study could provide valuable insights into new ways to support individuals with Alcohol Use Disorder in improving their social interactions and managing their alcohol use.

Participants in the study will be randomly assigned to receive either Sunobinop or the placebo. The medication will be taken in tablet form, with doses of 0.5 mg, 1 mg, or 2 mg, depending on the group assignment. The study will last for a period of eight weeks, during which participants will take the medication daily. Throughout the study, participants will be asked to keep a daily diary of their alcohol consumption and attend regular clinic visits for monitoring.

The purpose of this study is to evaluate whether Sunobinop can effectively reduce the percentage of heavy drinking days in individuals with moderate to severe Alcohol Use Disorder. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for those struggling with AUD.

The purpose of the study is to assess how effective the combination of 800mg or 1200mg of oral CBD with 50mg of oral Naltrexone is in reducing alcohol cravings compared to a placebo. Participants will take part in a series of visits over a period of time, where they will receive either the active treatment or a placebo. The study will monitor changes in alcohol craving levels, quality of life, and other related symptoms throughout the trial.

Participants will be asked to attend several visits, where they will undergo assessments to measure their alcohol cravings and other health indicators. The study will also track changes in mood, anxiety, and overall well-being. This research aims to provide insights into how Cannabidiol and Naltrexone can work together to help individuals manage their alcohol dependence more effectively.

Participants in the study will receive either tirzepatide or a placebo for a period of up to 26 weeks. The study will monitor changes in alcohol consumption, specifically looking at the number of heavy drinking days, which are defined as days with a high intake of alcohol. Additionally, the study will evaluate other factors such as alcohol cravings, overall alcohol consumption, and quality of life. The effects of tirzepatide on symptoms of schizophrenia and other health parameters will also be assessed.

The trial will involve regular assessments to track progress, including the use of questionnaires and tests to measure alcohol use and mental health. Some participants may also undergo additional evaluations, such as fMRI scans, to study brain activity related to alcohol cues. The goal is to determine if tirzepatide can provide a beneficial treatment option for individuals with both schizophrenia and alcohol use disorder.

The study will compare the effects of psilocybin capsules to a placebo to determine if the treatment can decrease the number of days when participants consume large amounts of alcohol. The medication being tested contains dry extract from Psilocybe cubensis, which is taken as an oral capsule.

The research will last 12 weeks after the single dose administration. During this time, researchers will monitor changes in participants’ drinking patterns and overall well-being. The study is designed so that neither the participants nor the researchers know who receives the actual medication or the placebo until the study is complete, which helps ensure accurate results.

Participants in the study will receive treatments through intravenous infusion, which means the medication is given directly into a vein. The study will compare the effects of ketamine with those of a placebo to see if there is a significant difference in how well the depression symptoms improve. The trial will also look at changes in alcohol cravings and consumption, as well as any side effects that may occur during the treatment sessions.

The study will take place over a period of time, with participants being monitored for changes in their symptoms and overall health. The goal is to gather information on how ketamine can help people with both depression and alcohol use disorder, and to understand its impact on their mental health and alcohol consumption habits. This research aims to provide valuable insights into potential new treatment options for individuals facing these challenges.

The purpose of the study is to assess how practical it is to conduct this type of research. Participants will be involved in two sessions where they will take psilocybin. The study will monitor various aspects, such as the number of participants who complete both sessions, changes in drinking habits, and any shifts in depression symptoms. The study will also collect information on participants’ experiences and any changes in their quality of life related to alcohol use.

Throughout the study, participants will be asked to complete questionnaires and provide blood samples to help researchers understand the effects of psilocybin on the body and mind. The study will also look at brain activity and other biological markers to gain a deeper understanding of how psilocybin might help with alcohol use disorder and depression. The trial is expected to continue until early 2026, with recruitment starting in 2024.

The purpose of the study is to determine if semaglutide can effectively reduce the amount of alcohol consumed by participants over a period of 26 weeks. Participants will receive semaglutide or a placebo through an injection under the skin, using a pre-filled pen. The study will monitor changes in alcohol consumption, including the number of days participants drink heavily, the total amount of alcohol consumed, and the number of days without alcohol. Additionally, the study will observe changes in body weight, blood pressure, and other health indicators.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their health. The trial aims to provide valuable insights into whether semaglutide can be a beneficial treatment for reducing alcohol intake in individuals with Alcohol Use Disorder and obesity. The study is expected to conclude in 2026, with results helping to inform future treatment options for these conditions.

The purpose of the study is to see if using CBD can help patients stay away from alcohol for a longer period after they leave the hospital. Participants will take part in the study for about six weeks, starting with their hospital stay and continuing for a month after they are discharged. During this time, they will receive either the CBD treatment or a placebo. The study will involve regular check-ups to monitor their progress and any side effects they might experience.

Throughout the study, participants will be asked to report their alcohol use and any symptoms they experience. This information will help researchers understand if CBD can effectively support people in maintaining their abstinence from alcohol. The study aims to provide valuable insights into whether CBD can be a helpful addition to traditional treatments for severe Alcohol Use Disorder.